Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LXRX
HOLDLexicon Pharmaceuticals, Inc. · Healthcare · United States · $1.0B · Avg Vol: $9M/d
37
StockRankGet insider-trade alerts
Q
42
V
25
M
62
P/E (TTM)
—
ROE
-16.0%
D/E
0.3x
Dividend %
—
Loading 1Y...
PRICE (1Y)+16.1%
SMA 50SMA 200
Close
$2.23
RSI (14)
42.0
52W High
$2.68
From 52W High
0.8%
SCORE BREAKDOWN
Quality
42
ROIC
-11.0%35.2
ROE
-16.0%33.1
GP/Assets
35.4%75.3
Op. Margin
-4.7%32.3
FCF/Assets
-15.6%23.4
Piotroski
111.4
Int. Cover
-2.2x32.5
D/E Ratio
0.28x42.8
Current Ratio
18.80x94.6
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-38.2x25.0
P/FCF
—N/A
P/B
4.8x29.0
P/S
14.6x20.9
Div Yield
—N/A
Momentum
62
52W High %
83%75.3
RS 6M
23%88.1
SMA 50/200
1.31x94.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-195%2.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.0B
P/E (Forward)
-11.1x
Gross Margin
94.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LXRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LXRX | Lexicon Pharmaceuticals, Inc.(you) | $1.0B | 37 | HOLD |
| CGEM | Cullinan Therapeutics, Inc. | $1.1B | 37 | HOLD |
| ANRO | Alto Neuroscience, Inc. | $940M | 35 | SELL |
| NVAX | Novavax, Inc. | $1.2B | 37 | HOLD |
| LBRX | LB Pharmaceuticals Inc | $1.0B | 42 | HOLD |
| MGTX | MeiraGTx Holdings plc | $1.1B | 33 | SELL |
| 0KCS.L | OPKO Health, Inc. | $734M | 37 | HOLD |
| FBRX | Forte Biosciences, Inc. | $1.1B | 32 | SELL |
| JBIO | Jade Biosciences, Inc. | $1.2B | 33 | SELL |
| CLYM | Climb Bio, Inc. | $735M | 39 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%